UNITY BIOTECHN. DL-0001
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also devel… Read more
Market Cap & Net Worth: UNITY BIOTECHN. DL-0001 (9U90)
UNITY BIOTECHN. DL-0001 (F:9U90) has a market capitalization of $282.26 (€274.98) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #49431 globally and #8314 in its home market, demonstrating a -57.14% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying UNITY BIOTECHN. DL-0001's stock price €0.03 by its total outstanding shares 9166 (9.17K).
UNITY BIOTECHN. DL-0001 Market Cap History: 2018 to 2026
UNITY BIOTECHN. DL-0001's market capitalization history from 2018 to 2026. Data shows change from $1.36 Million to $282.26 (-66.16% CAGR).
UNITY BIOTECHN. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how UNITY BIOTECHN. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9U90 by Market Capitalization
Companies near UNITY BIOTECHN. DL-0001 in the global market cap rankings as of March 18, 2026.
Key companies related to UNITY BIOTECHN. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
UNITY BIOTECHN. DL-0001 Historical Marketcap From 2018 to 2026
Between 2018 and today, UNITY BIOTECHN. DL-0001's market cap moved from $1.36 Million to $ 282.26, with a yearly change of -66.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €282.26 | 0.00% |
| 2025 | €282.26 | -96.93% |
| 2024 | €9.18K | -42.28% |
| 2023 | €15.91K | -33.16% |
| 2022 | €23.80K | -77.53% |
| 2021 | €105.94K | -73.00% |
| 2020 | €392.34K | -34.49% |
| 2019 | €598.86K | -56.10% |
| 2018 | €1.36 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of UNITY BIOTECHN. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $282.26 USD |
| MoneyControl | $282.26 USD |
| MarketWatch | $282.26 USD |
| marketcap.company | $282.26 USD |
| Reuters | $282.26 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.